AABB's Statements to the Blood Product Advisory Committee

Joint Statement Before BPAC on Cold Stored Platelets for Transfusion (PDF)
Joint Statement Before BPAC on Strategies to Control the Risk of Bacterial Contamination in Platelets for Transfusion (PDF)
Joint Statement Before BPAC on August 2016 Zika Guidance Document (PDF)
Statement Before BPAC on “Blood Donor Deferral Policy for Reducing the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products (PDF)
Joint Statement Before BPAC on FDA “Recommendation for Donor Screening, Deferral and Product Management to Reduce the Risk of Transfusion-Transmission of Zika Virus,” August 2016 Guidance (PDF)
Statement Before BPAC on the Management of Iron Deficiency Associated with Blood Donation (PDF)
Statement Before BPAC on Strategies for Implementation of Testing for Babesia microti in Blood Donors (PDF)

For more information, refer to the comprehensive list of statements and comments to FDA.

Related News

REGULATORY UPDATE: FDA Expects IRA Final Guidance Before End of PHE

February 03, 2023
Peter Marks to Join Thursday Hot Topic Discussion on Individual Risk Assessment

February 01, 2023
REGULATORY UPDATE: FDA Releases 2023 Guidance Agenda

January 31, 2023